By Denny Jacob
Shares of GeneDx Holdings shot up 24% following higher-than-expected revenue in its fourth quarter.
Shares were trading around $95. Over the last year, the stock is up nearly 1800%.
The patient health intelligence company recorded revenue of $95.3 million, up 64% from $58.1 million in the prior-year period. Analysts polled by FactSet had expected $82.2 million.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 18, 2025 10:14 ET (15:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.